Optomed Oyj

Ticker/ISIN

OPTOMED

FI4000410881

Marknad/Land

Main Market, Helsinki

Sweden

Senaste sammanfattade pressmeddelande från Optomed Oyj

Optomed Plc's Nomination Board has proposed several items for the next Annual General Meeting. They suggest that the Board of Directors should have seven members for the term ending at the 2026 meeting. Anna Tenstam has indicated she will not seek re-election. The proposed remuneration for the Board remains unchanged, with 40% paid in Optomed shares and 60% in cash, and a meeting fee of EUR 300 for committee chairmen and EUR 200 for committee members per meeting. The remuneration will be paid annually in August after the H1 report is released. The Nomination Board includes Petri Salonen as an expert member and Vesa Vanha-Honko as chairman. Optomed is a Finnish company specializing in handheld fundus cameras and related software, focusing on eye-screening devices and solutions for blinding eye diseases.

Övrig information som ska lämnas enligt börsens regler: Proposal of Optomed's Nomination Board

för 2 månader sedan

Optomed Plc has announced a change in its shareholdings as reported by Danske Bank A/S, which now holds 4.86% of Optomed's shares and voting rights as of November 12, 2024. Previously, Danske Bank held 5.08%. The total number of Optomed's registered shares is 19,630,397, with each share granting one vote. The notification includes details of the shares and voting rights distribution, with the majority held by Finnish Fund and a minor portion by Danica Pension Livsforsikringsaktie. Optomed is a Finnish company specializing in handheld fundus cameras and related software, focusing on eye disease diagnostics and operating in over 60 countries. Further inquiries can be directed to Sakari Knuutti, CFO of Optomed.

Flaggningsanmälan: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

för 4 månader sedan

Optomed Plc announced that a total of 62,900 new shares have been subscribed through its 2018C stock options as of October 25, 2024, amounting to a subscription price of EUR 220,150. These shares have been added to the reserve for invested unrestricted equity. Following the registration, the total number of shares is now 19,693,297. The new shares were registered in the Trade Register on November 13, 2024, and will be traded on Nasdaq Helsinki alongside existing shares starting November 14, 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software, focusing on eye disease diagnostics and operating in over 60 countries. For more information, contact Sakari Knuutti, CFO, at sakari.knuutti@optomed.com.

Totalt antal rösträtter och kapital: Share subscriptions based on stock options 2018C

för 4 månader sedan

Optomed Plc announced that it has received a EUR 1.5 million order from a US screening service provider, prompting the company to revise its full-year 2024 revenue outlook. Initially expecting a revenue decrease from 2023, Optomed now anticipates revenue to remain at the same level as the previous year. The order is a traditional device capex transaction without AI services or recurring revenue. Due to low device stock levels, Optomed may face limitations in making additional large capex deliveries in the fourth quarter of 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and screening software, with operations in Finland, the US, and China, and sales in over 60 countries.

Insiderinformation: Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook

för 4 månader sedan

Optomed Plc reported a decline in financial performance for Q3 2024, with revenue decreasing by 26.3% compared to Q3 2023. The Devices segment saw a significant drop of 55.5% in revenue, mainly due to the absence of large orders that had been present in the previous year. The Software segment experienced a smaller decline of 4.0%. The company's gross margin fell to 54.4% from 67.4%, influenced by an inventory revaluation. EBITDA was reported at EUR -814 thousand, a sharp decline from the previous year. Optomed's net debt increased by 70.6%, reaching EUR -8,343 thousand. Despite these challenges, the company highlighted progress in the oculomics field and the commercialization of Aurora AEYE, with new market opportunities and strategic partnerships. Optomed expects a decrease in full-year 2024 revenue compared to 2023. The company maintains a strong cash position of EUR 11 million. The Annual General Meeting elected the Board of Directors and confirmed no dividend payout for 2023. Optomed continues to focus on innovation in healthcare diagnostics and strategic partnerships.

Interimsrapport: Optomed Plc: Interim Report, January - September 2024

för 4 månader sedan

Optomed Plc announced on September 30, 2024, that it has received a notification from Danske Bank A/S regarding a change in holdings. As of September 26, 2024, Danske Bank A/S holds 5.08% of Optomed's total shares and voting rights, amounting to 997,607 shares out of the company's 19,630,397 registered shares. This disclosure is made under Chapter 9, Section 10 of the Finnish Securities Markets Act. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software for diagnosing eye diseases, with operations in over 60 countries. Further inquiries can be directed to Sakari Knuutti, CFO of Optomed.

Flaggningsanmälan: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

för 6 månader sedan

Optomed Plc has issued a profit warning, revising its full-year 2024 revenue outlook to a decrease from 2023. This change is due to postponed key deliveries in the Software Segment and slower-than-expected sales in the Devices Segment. Despite anticipated strong revenue growth in the US and China, the overall revenue is expected to decline. The Q3-2023 period had been positively impacted by a significant delivery worth approximately EUR 800,000 to Valencia, Spain. Sales of the Optomed Aurora AEYE have begun and received positive feedback, but its recurring revenue service will not significantly affect the 2024 revenue outlook. The previous outlook, announced in February 2024, had anticipated revenue growth for the year. Optomed will publish its Interim Report for January-September 2024 on 7 November 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and screening software, with operations in Finland, the US, and China, and sales in over 60 countries.

Insiderinformation: Inside information, profit warning: Optomed decreases its full year outlook

för 6 månader sedan

On 11 September 2024, Optomed Plc announced the composition of its Nomination Board based on the shareholder register as of 2 September 2024. The shareholders represented on the Nomination Board are OP-Rahastoyhtiö Oy (OP funds), SP-Rahastoyhtiö Oy (SP Funds), and Danske Invest Rahastoyhtiö Oy (Danske Funds). Petri Salonen, Chairman of Optomed’s Board of Directors, will serve as the Nomination Board's expert member. The Nomination Board, consisting of representatives from Optomed's three largest shareholders and the Chairman of the Board, is tasked with preparing proposals on the composition and remuneration of the Board of Directors for the next Annual General Meeting. The proposals are to be submitted by 31 January 2025. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and eye-screening devices, with operations in over 60 countries. Further inquiries can be directed to Petri Salonen at petri.salonen@optomed.com.

Övrig information som ska lämnas enligt börsens regler: Composition of Optomed's Nomination Board

för 6 månader sedan

Threads

Föregående

Sida 3

Nästa